Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study

Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease

The purpose of this study is to evaluate safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation. The hypothesis to be tested is that the cells are safe to infuse and that they have a positive clinical effect.

Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1-2x10^6 cells/kg at one or more occasions dependent on clinical response.

Inclusion Criteria:

• Acute graft versus host disease grade 2-4.
• Are on calcineurin inhibitor and high dose corticosteroids.

Exclusion Criteria:

None.